Pirtobrutinib

Buy Pirtobrutinib (Jaypirca) tablets in India
Generic Name/API:Pirtobrutinib
Packaging:50 mg (30 tablets per bottle) and 100 mg (60 tablets per bottle).
Storage:Store Pirtobrutinib tablets at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F)
Dosage:For dosage information, please visit the General Information section.
Strength:Available in 50 mg and 100 mg tablets.
Indication:Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor.

Pirtobrutinib a kinase inhibitor indicated for the treatment of:

  • Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
    This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • Adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor.

Strength:

Available in 50 mg and 100 mg tablets.

Dosage: 

Recommended dosage is 200 mg orally once daily, swallow whole with water, with or without food.

Adverse Reactions: 

Most common adverse reactions (≥ 30%), including laboratory abnormalities, are fatigue, neutrophil count decreased, platelet count decreased, hemoglobin decreased, leukocytes decreased, lymphocyte count decreased and calcium decreased.

Storage:

Store Pirtobrutinib tablets at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F)

  • Infections: Monitor for signs and symptoms of infection, evaluate promptly, and treat. 
  • Hemorrhage: Monitor for bleeding and manage appropriately.
  • Cytopenias: Monitor complete blood counts during treatment. 
  • Cardiac Arrythmias: Monitor for symptoms of arrhythmias and manage appropriately. 
  • Second Primary Malignancies: Other malignancies have developed, including skin cancers and other carcinomas. Monitor and advise patients to use sun protection. 
  • Hepatotoxicity, Including Drug-Induced Liver Injury: Monitor hepatic function throughout treatment. 
  • Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of potential risk to a fetus and to use effective contraception.

Process to Import Medicine

FAQ

Pirtobrutinib (Jaypirca) is a next-generation, non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor used to treat certain B-cell blood cancers. It is designed to remain effective even in some patients whose disease has become resistant to first-generation BTK inhibitors.

Pirtobrutinib is FDA-approved for the treatment of:

  • Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults previously treated with a covalent BTK inhibitor. 
  • Relapsed or refractory mantle cell lymphoma (MCL) after at least two prior lines of therapy, including a BTK inhibitor. (This indication remains under accelerated approval.)

Jaypirca (Pirtobrutinib) blocks the BTK protein, which plays a key role in the growth and survival of malignant B cells. Unlike covalent BTK inhibitors, it binds reversibly to BTK and can inhibit both wild-type and many mutated forms of the protein, helping overcome resistance.

The recommended dose is 200 mg orally once daily, with or without food. Tablets should be swallowed whole and taken at approximately the same time each day.

If you remember within 12 hours, take the missed dose as soon as possible. If more than 12 hours have passed, skip the missed dose and take the next dose at the regular time. Do not take two doses together.

Serious adverse effects may include:

  • Serious infections 
  • Bleeding (hemorrhage) 
  • Low blood cell counts (cytopenias) 
  • Heart rhythm problems such as atrial fibrillation 
  • Liver injury 
  • Development of second primary cancers, including skin cancer 
  • Harm to an unborn baby during pregnancy

Some medicines can affect how pirtobrutinib works, particularly:

  • Strong CYP3A inhibitors 
  • Strong or moderate CYP3A inducers 
  • Certain drugs transported by P-gp, BCRP, CYP2C8, CYP2C19, or CYP3A 

Always inform your healthcare provider about all prescription medicines, over-the-counter drugs, and herbal supplements you take. 

The price of Pirtobrutinib (Jaypirca) tablets in India may vary, as the medicine is not approved in India and must be imported. Pricing depends on product availability, import-related costs, and applicable regulatory requirements. For the latest pricing details and availability, please contact 24/7 QualityMeds at +919967979080.

To buy Pirtobrutinib (Jaypirca) tablets in Delhi, a valid prescription from a registered healthcare practitioner is required. 24/7 QualityMeds assists with medicine availability, prescription verification, and delivery in compliance with applicable regulatory requirements.

To buy Pirtobrutinib (Jaypirca) tablets online in India, a valid prescription and applicable regulatory documentation are required. 24/7 QualityMeds assists with prescription verification, import documentation, and the lawful procurement of the medicine in accordance with Indian regulations.

Related products